Mineralys Therapeutics (MLYS) Equity Ratio (2022 - 2026)

Mineralys Therapeutics has disclosed Equity Ratio across 5 years of filings, most recently posting 0.98 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.98, up 1.58% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.98 (up 1.58% YoY), and the FY2025 annual result was 0.98, up 5.2% from the prior year.
• Equity Ratio came in at 0.98 for Q1 2026 at Mineralys Therapeutics, roughly flat from 0.98 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q2 2023 to a low of 0.46 in Q4 2022.
• The 5-year median for Equity Ratio is 0.95 (2023), against an average of 0.85.
• Across the five-year window, Equity Ratio soared 309.83% in 2023 and decreased 7.15% in 2024, its largest moves.
• Mineralys Therapeutics' Equity Ratio stood at 0.46 in 2022, then soared by 309.83% to 0.96 in 2023, then decreased by 3.08% to 0.93 in 2024, then rose by 5.2% to 0.98 in 2025, then climbed by 0.03% to 0.98 in 2026.
• The last three Equity Ratio figures came in at 0.98 (Q1 2026), 0.98 (Q4 2025), and 0.96 (Q3 2025), per Business Quant data.